Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Drug Carrier Systems For Anticancer Agents

Hiroyuki Koide, T. Asai, K. Shimizu, N. Oku
Published 2019 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1016/j.canlet.2008.05.009
Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Y. Katanasaka (2008)
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
A. Kudelka (1997)
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
T. Browder (2000)
10.1016/J.JCONREL.2006.12.024
Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model.
S. Yonezawa (2007)
10.2174/092986707780059571
The structure and main functions of aminopeptidase N.
Y. Luan (2007)
10.1002/1097-0142(20001001)89:7<1626::AID-CNCR28>3.0.CO;2-T
Usefulness of positron emission tomographic visualization for examination of in vivo susceptibility to metastasis
H. Kikkawa (2000)
10.1134/S0006297908070031
Mechanisms of angiogenesis
A. F. Karamysheva (2008)
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
T. Fong (1999)
Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470.
M. Kanamori (2007)
10.1126/SCIENCE.277.5323.225
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
G. Giannelli (1997)
10.1124/jpet.108.144451
Therapeutic Effect of Lecithinized Superoxide Dismutase against Colitis
T. Ishihara (2009)
10.1016/J.JCONREL.2006.05.028
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.
Justin M Saul (2006)
10.1016/J.EJPB.2006.11.022
Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: characterization and in vitro evaluation.
Sachiro Kakinoki (2007)
10.1007/978-1-4615-2554-7_4
The transferrin receptor and the release of iron from transferrin.
P. Aisen (1994)
10.1007/s00441-003-0774-5
Integrins in angiogenesis: multitalented molecules in a balancing act
K. Hodivala-Dilke (2003)
10.1517/13543784.9.6.1383
TNP-470: an angiogenesis inhibitor in clinical development for cancer
E. Kruger (2000)
10.1038/370061A0
A matrix metalloproteinase expressed on the surface of invasive tumour cells
H. Sato (1994)
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
F. Pastorino (2003)
10.1038/nm0602-567
The role of Th1/Th2 polarization in mucosal immunity
M. Neurath (2002)
10.1074/jbc.272.4.2446
Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules*
E. Ohuchi (1997)
10.1158/0008-5472.CAN-04-1038
Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar
Y. Li (2004)
10.1016/S0168-3659(03)00240-2
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
R. Schiffelers (2003)
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
M. Yamaoka (1993)
10.1016/S0168-3659(03)00218-9
Drug delivery in polymeric micelles: from in vitro to in vivo.
N. Rapoport (2003)
10.1056/NEJM197108122850711
Transplacental carcinogenesis by stilbestrol.
J. Folkman (1971)
10.1002/eji.200424993
Both IL‐12 and IL‐18 contribute to small intestinal Th1‐type immunopathology following oral infection with Toxoplasma gondii, but IL‐12 is dominant over IL‐18 in parasite control
Anna Vossenkaemper (2004)
10.2337/diacare.13.9.911
Insulin Administration via Liposomes
R. S. Spangler (1990)
10.1016/J.IJROBP.2005.06.045
In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053).
S. Formenti (2005)
10.1016/S0014-5793(98)01511-7
GD1α‐replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis
D. Ishikawa (1998)
10.1016/J.IJPHARM.2007.06.010
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
R. Suzuki (2008)
10.1083/JCB.148.3.615
Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5
N. Koshikawa (2000)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.1016/S0014-5793(00)01144-3
Possible role of immune surveillance at the initial phase of metastasis produced by B16BL6 melanoma cells
H. Kikkawa (2000)
10.1007/s11095-008-9673-5
Multifunctional Polymeric Micelles for Enhanced Intracellular Delivery of Doxorubicin to Metastatic Cancer Cells
X. Xiong (2008)
10.3322/canjclin.53.1.5
Cancer Statistics, 2003
A. Jemal (2003)
10.1111/j.1349-7006.2006.00291.x
Identification of oligopeptides binding to peritoneal tumors of gastric cancer
N. Akita (2006)
10.1126/SCIENCE.279.5349.377
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
W. Arap (1998)
10.1016/j.ejpb.2007.10.017
Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins.
A. Grenha (2008)
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
T. Yanase (1993)
10.1093/emboj/cdf411
CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain
H. Mori (2002)
10.1126/SCIENCE.7512751
Requirement of vascular integrin alpha v beta 3 for angiogenesis.
P. Brooks (1994)
10.1016/0005-2736(91)90162-2
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times.
D. Lasic (1991)
10.1016/j.ejpb.2008.11.010
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
H. Maeda (2009)
10.1023/A:1016009313548
Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes
H. Takeuchi (2004)
10.1038/sj.gt.3302090
Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice
N. Okada (2003)
10.1016/J.JCONREL.2005.09.034
Block copolymer micelles: preparation, characterization and application in drug delivery.
G. Gaucher (2005)
10.1023/A:1006317125454
Molecular Role(s) for Integrins in Human Melanoma Invasion
R. Seftor (2004)
10.1111/j.1349-7006.2007.00474.x
Antitumor effect of TNP‐470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound
M. Emoto (2007)
10.1016/S0014-5793(01)03265-3
Suppression of tumor growth by novel peptides homing to tumor‐derived new blood vessels
T. Asai (2002)
10.1016/S0168-3659(02)00411-X
Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats.
H. Takeuchi (2003)
10.1016/0006-291X(91)91529-L
Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.
M. Kusaka (1991)
Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention.
F. Muggia (1999)
10.1016/S0022-2836(64)80115-7
NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE.
A. Bangham (1964)
10.1016/J.IJPHARM.2007.04.037
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
H. Hatakeyama (2007)
10.1016/J.JCONREL.2004.07.033
Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
N. Maeda (2004)
10.1038/sj.onc.1205347
Anti-neovascular therapy using novel peptides homing to angiogenic vessels
N. Oku (2002)
10.1182/BLOOD.V97.8.2323
Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen.
M. Seandel (2001)
10.1038/sj.bjc.6603855
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
T. Hamaguchi (2007)
10.1021/BM060967G
Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
X. Xiong (2007)
10.1158/0008-5472.CAN-06-1605
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
F. Koizumi (2006)
10.1016/J.IJPHARM.2007.07.013
A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics.
H. Zhang (2008)
10.1111/j.1463-1318.2008.01487.x
A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
Y. Suzuki (2008)
10.1111/j.1349-7006.2005.00054.x
Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer
K. Yanagihara (2005)
10.1016/S0014-5793(00)01110-8
Suppression of GD1α ganglioside‐mediated tumor metastasis by liposomalized WHW‐peptide
M. Takikawa (2000)
10.1093/AJCN/75.1.79
An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations.
M. Noakes (2002)
10.1016/0005-2736(94)90003-5
Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity.
V. Torchilin (1994)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1038/nrc905
Clinical translation of angiogenesis inhibitors
R. Kerbel (2002)
10.1038/348555A0
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
D. Ingber (1990)
10.1016/S0168-3659(00)00373-4
Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting.
R. Igarashi (2001)
10.1038/sj.bjc.6602479
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
T. Hamaguchi (2005)
10.1074/jbc.M900280200
Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors*
De-Kuan Chang (2009)
10.1016/S0014-5793(97)00905-8
Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo
K. Maruyama (1997)
10.1016/S0046-8177(99)90202-2
Progression-related expression of beta3 integrin in melanomas and nevi.
P. V. Van Belle (1999)
10.1074/JBC.270.2.801
The C-terminal Region of Membrane Type Matrix Metalloproteinase Is a Functional Transmembrane Domain Required for Pro-gelatinase A Activation (*)
J. Cao (1995)
10.1074/jbc.270.40.23730
Thrombin Induces the Activation of Progelatinase A in Vascular Endothelial Cells
S. Zucker (1995)
10.1038/nbt1415
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
Ofra Benny (2008)
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.
C. Logothetis (2001)
10.3109/10611869909085500
Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system.
M. Yokoyama (1999)
10.1002/(SICI)1097-0215(19980821)79:4<429::AID-IJC20>3.0.CO;2-Z
Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase‐polymerase chain reaction and cytology
Y. Kodera (1998)
10.1023/A:1006304806799
Cell Adhesion Molecules in the Development and Progression of Malignant Melanoma
J. Johnson (2004)
10.1093/NASS/49.1.17
Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery.
K. Kataoka (2005)
10.1038/nrd1033
Effect of pegylation on pharmaceuticals
J. Harris (2003)
10.1126/SCIENCE.275.5302.964
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
T. Asahara (1997)
10.1016/J.COLSURFB.2004.12.017
Dialkylphosphatidylcholine and egg yolk lecithin for emulsification of various triglycerides.
Tomoko Nii (2005)
A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
P. Bhargava (1999)
10.1038/sj.bjc.6600580
Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites
C. Sakakura (2002)
10.1248/BPB.30.972
In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
K. Atobe (2007)
10.1021/BI971705P
Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of action.
N. Luciani (1998)
10.1021/BC015561+
Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
R. J. Kok (2002)
10.1038/nm1213
Mucosal immunity and vaccines
J. Holmgren (2005)
10.1016/S0955-0674(02)00363-0
The cell surface: the stage for matrix metalloproteinase regulation of migration.
M. Seiki (2002)
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
F. Curnis (2002)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1111/j.1349-7006.2009.01103.x
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Y. Matsumura (2009)
10.3201/EID0602.000204
Vaccines for mucosal immunity to combat emerging infectious diseases.
F. V. van Ginkel (2000)
10.1158/1078-0432.CCR-0221-3
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
M. Zangari (2004)
10.1016/S0955-0674(96)80115-3
Integrins and cancer.
J. Varner (1996)
beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids.
A. Awad (1996)
10.1007/s002620050345
In vivo antitumor effects of murine interferon- γ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites
M. J. Micallef (1997)



Semantic Scholar Logo Some data provided by SemanticScholar